Cryoport, Inc. (NASDAQ:CYRX) Receives $12.29 Consensus Target Price from Brokerages

Cryoport, Inc. (NASDAQ:CYRX) has earned an average recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $12.29.

CYRX has been the subject of several research reports. Roth Mkm decreased their target price on Cryoport from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, November 8th. Needham & Company LLC reissued a “buy” rating and issued a $11.00 target price on shares of Cryoport in a research report on Friday, January 17th. Finally, Guggenheim assumed coverage on Cryoport in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 price objective for the company.

Cryoport Stock Up 0.6 %

Shares of NASDAQ:CYRX opened at $6.77 on Friday. Cryoport has a 52-week low of $5.32 and a 52-week high of $20.10. The firm has a market capitalization of $334.64 million, a P/E ratio of -2.00 and a beta of 1.59. The stock has a 50 day moving average price of $7.72 and a 200-day moving average price of $7.78. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70.

Insider Activity at Cryoport

In other Cryoport news, Director Ramkumar Mandalam sold 7,369 shares of Cryoport stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $7.46, for a total value of $54,972.74. Following the completion of the sale, the director now owns 59,497 shares of the company’s stock, valued at approximately $443,847.62. This trade represents a 11.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jerrell Shelton sold 50,000 shares of Cryoport stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $6.51, for a total value of $325,500.00. Following the completion of the sale, the chief executive officer now directly owns 731,897 shares of the company’s stock, valued at approximately $4,764,649.47. The trade was a 6.39 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 59,869 shares of company stock valued at $396,673 in the last 90 days. Corporate insiders own 10.10% of the company’s stock.

Institutional Trading of Cryoport

A number of institutional investors and hedge funds have recently modified their holdings of CYRX. Point72 Asia Singapore Pte. Ltd. increased its holdings in shares of Cryoport by 148.7% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock worth $28,000 after purchasing an additional 2,120 shares in the last quarter. Lazard Asset Management LLC purchased a new position in shares of Cryoport in the 4th quarter worth $51,000. Avanza Fonder AB purchased a new position in shares of Cryoport in the 4th quarter worth $64,000. Quarry LP purchased a new position in shares of Cryoport in the 4th quarter worth $69,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of Cryoport in the 3rd quarter worth $82,000. Institutional investors own 92.90% of the company’s stock.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.